ロード中...
Phase II Chemoprevention Trial with High Dose Fenretinide for Oral Pre-Malignant Lesions
BACKGROUND: In a previous phase II trial, we demonstrated that fenretinide 200 mg/day had limited activity in retinoid-refractory leukoplakia (34% response rate), possibly due to the lack of achievement of high serum levels which would be required to elicit retinoid-receptor independent apoptosis in...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4161148/ https://ncbi.nlm.nih.gov/pubmed/19139014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-08-0100 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|